The Blood Transfusion Diagnostic Testing market quantifies and segments key technologies (immunoassay and nucleic acid testing), distinct instrumentation (immunoassay systems, NAT-based systems, and automated blood grouping and typing systems), and broad test price points (net to the manufacturer). The two basic sub-segments of this market are Blood Processing (BP), which includes immunoassay and nucleic acid-based test kits as well as instruments used in the QC/QA of donated material (blood, plasma, and other donated products), and Blood Grouping and Typing (BGT), which covers ABO/Rh and other blood type characterization tests as well as associated instruments.
Market estimates include mandated whole blood screening tests, those either mandated or performed as "standard practice" on plasma, and NAT/pool testing for Hepatitis, HIV, and bacterial contamination. While the consultants specifically exclude virology tests that are conducted for diagnosis and monitoring from this market, it is duly recognized that overlap in this area occurs in many countries.
Five- and 10-year market projections take into account to-be-emerging analytes and to-be-discovered/characterized infectious agents, as well as the application of technologies not used in routine practice in 2005.
End-User Segments
Central hospital/private laboratories, free standing blood donor (and plasma testing) laboratories, and hospital blood banks. Future application in POC/NPT.
The leading worldwide manufacturers of transfusion diagnostic test kits and systems include, but are not limited to:
Regional suppliers of virology and BGT test products are provided on an aggregated basis only in the "Other Companies" test category, but are tracked internally given the impact they may have on selected country markets (>15 additional secondary competitors).
Market Assessment/Monitoring Reports:
Relevant Conferences: